Enhanced susceptibility of B lymphoma cells to measles virus by Epstein-Barr virus type III latency that upregulates CD150/signaling lymphocytic activation molecule

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

(2013) Jeong Heo et al.   NATURE MEDICINE

Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

(2012) E. M. Karapanagiotou et al.   CLINICAL CANCER RESEARCH

Attenuated Oncolytic Measles Virus Strains as Cancer Therapeutics

(2012) P. Msaouel et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Phase II Trial of Intravenous Administration of Reolysin® (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma

(2012) Evanthia Galanis et al.   MOLECULAR THERAPY

Oncolytic virotherapy

(2012) Stephen J Russell et al.   NATURE BIOTECHNOLOGY

Oncolytic Viruses in the Treatment of Cancer: A Review of Current Strategies

(2012) Md. Zeyaullah et al.   PATHOLOGY & ONCOLOGY RESEARCH

Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus

(2011) K Zaoui et al.   CANCER GENE THERAPY

Cytokine signatures of transformed B cells with distinct Epstein-Barr virus latencies as a potential diagnostic tool for B cell lymphoma

(2011) Kosuke Miyauchi et al.   CANCER SCIENCE

Genetic Characterization of Measles Vaccine Strains

(2011) B. Bankamp et al.   JOURNAL OF INFECTIOUS DISEASES

Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer

(2010) E. Galanis et al.   CANCER RESEARCH

Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics

(2010) K.J. Harrington et al.   CYTOKINE & GROWTH FACTOR REVIEWS

CD150 regulates JNK1/2 activation in normal and Hodgkin's lymphoma B cells

(2010) Mariya Y Yurchenko et al.   IMMUNOLOGY AND CELL BIOLOGY

Oncolytic Viruses Move Forward in Clinical Trials

(2010) K. Rowan   JNCI-Journal of the National Cancer Institute

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

(2009) Neil N. Senzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Reduced ability of hemagglutinin of the CAM-70 measles virus vaccine strain to use receptors CD46 and SLAM

(2009) Seiichi Kato et al.   VACCINE

Oncolytic viruses: a novel form of immunotherapy

(2008) Robin J Prestwich et al.   Expert Review of Anticancer Therapy